PRACTICE
Evaluation of Atherosclerotic Plaque Progression by Coronary Computed Tomography Angiography and Intracoronary Imaging Techniques in Patients With Coronary Artery Disease
Sponsor study identifier
observational
50,000
1 country
2
Study Start
January 1, 2016
Actual (reported)Primary Completion
May 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This is a combined cohort study with retrospectively and prospectively enrolled coronary artery disease (CAD) patients. All the patients will undergo clinical follow-up for up to 5 years, and repeat coronary CTA will be conducted after 2 years. Comprehensive morphological and functional plaque analysis will be performed. The impact of these morphological and functional parameters, alongside cardiometabolic factors and pharmacological treatments on plaque progression and the occurrence of major adverse cardiovascular events (MACEs) will be analyzed. In addition, intracoronary imaging techniques will be used to improve the accuracy of plaque analysis by coronary CTA.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2016
Actual (reported)January 14, 2025
Actual (reported)January 27, 2025
Actual (reported)May 31, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
May 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Changes in total atheroma volume (TAV)
changes in TAV in whole heart and in target lesions measured by coronary CTA and quantification analysis at baseline and during follow-up
24 months
Major cardiovascular events (MACEs)
5 years
Cardiovascular death
5 years
Myocardial infarction
5 years
Unplanned revascularization
5 years
Changes in calcified plaque volume
24 months
Subjects with CAD detected by coronary CTA are consecutively enrolled. All the patients will undergo clinical follow-up for up to 5 years. Repeat coronary CTA will be conducted after 2 years.
This is a combination of retrospective and prospective cohort studies. Patients with clinical angina pectoris or suspected CAD who undergo coronary CTA scan, including outpatient and hospitalized patients, are consecutively enrolled.
CAAC East China Aviation Personnel Medical Appraisal Center, Civil Aviation Shanghai Hospital
Shanghai, 200000, China
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, 200025, China
Blood sample at baseline and follow-up
Ruiyan Zhang, M.D., Ph.D.
Ruijin Hospital
First Submitted
January 14, 2025
First Posted
January 27, 2025
Study Start
January 1, 2016
Actual (reported)Primary Completion
May 31, 2027
Estimatedthe Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy
Contact the study team to confirm eligibility.
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
May 31, 2030
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
January 27, 2025
Record last verified: 2025-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: